Reviews of Translational Medicine and Genomics in Cardiovascular Disease: New Disease Taxonomy and Therapeutic Implications. Cardiomyopathies: Therapeutics Based on Molecular Phenotype

Journal of the American College of Cardiology

Volumn 49, Issue 12, 2007, Pages 1251-1264

  Ashrafian, Houman ^a   Watkins, Hugh ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

APOPTOSIS; ARRHYTHMOGENESIS; CALCIUM TRANSPORT; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CONGESTIVE CARDIOMYOPATHY; CYTOSKELETON; DISEASE CLASSIFICATION; DNA MICROARRAY; ENERGY TRANSFER; GENETIC ANALYSIS; GENETIC SCREENING; GENETIC VARIABILITY; HEART RIGHT VENTRICLE DYSPLASIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MORPHOLOGY; PATHOPHYSIOLOGY; PATIENT CARE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; RESTRICTIVE CARDIOMYOPATHY; REVIEW; SARCOMERE; TAXONOMY;

CARDIOMYOPATHIES; CARDIOVASCULAR DISEASES; GENETIC SCREENING; GENOMICS; HUMANS; PHENOTYPE;

EID: 33947531466     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2006.10.073     Document Type: Review

References (83)

1. Quackenbush J. Microarray analysis and tumor classification. N Engl J Med 354 (2006) 2463-2472
2. Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
3. Helgadottir A., Manolescu A., Thorleifsson G., et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 36 (2004) 233-239
4. Maron B.J., Towbin J.A., Thiene G., et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 113 (2006) 1807-1816
5. Teare D. Asymmetrical hypertrophy of the heart in young adults. Br Heart J 20 (1958) 1-8
6. Maron B.J., Gardin J.M., Flack J.M., Gidding S.S., Kurosaki T.T., and Bild D.E. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA study. Coronary Artery Risk Development in (Young) Adults. Circulation 92 (1995) 785-789
7. Maron B.J., Shirani J., Poliac L.C., Mathenge R., Roberts W.C., and Mueller F.O. Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. JAMA 276 (1996) 199-204
8. Jarcho J.A., McKenna W., Pare J.A., et al. Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. N Engl J Med 321 (1989) 1372-1378
9. Geisterfer-Lowrance A.A., Kass S., Tanigawa G., et al. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell 62 (1990) 999-1006
10. Maron B.J., Seidman J.G., and Seidman C.E. Proposal for contemporary screening strategies in families with hypertrophic cardiomyopathy. J Am Coll Cardiol 44 (2004) 2125-2132
11. Seidman J.G., and Seidman C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell 104 (2001) 557-567
12. Thierfelder L., Watkins H., MacRae C., et al. Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell 77 (1994) 701-712
13. Geier C., Perrot A., Ozcelik C., et al. Mutations in the human muscle LIM protein gene in families with hypertrophic cardiomyopathy. Circulation 107 (2003) 1390-1395
14. Marian A.J. Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. Lancet 355 (2000) 58-60
15. Redwood C.S., Moolman-Smook J.C., and Watkins H. Properties of mutant contractile proteins that cause hypertrophic cardiomyopathy. Cardiovasc Res 44 (1999) 20-36
16. Blair E., Redwood C., Ashrafian H., et al. Mutations in the g2 subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Hum Mol Genet 10 (2001) 1215-1220
17. Sweeney H.L., Feng H.S., Yang Z., and Watkins H. Functional analyses of troponin T mutations that cause hypertrophic cardiomyopathy: Insights into disease pathogenesis and troponin function. Proc Natl Acad Sci U S A 95 (1998) 14406-14410
18. Ashrafian H., Redwood C., Blair E., and Watkins H. Hypertrophic cardiomyopathy: a paradigm for myocardial energy depletion. Trends Genet 19 (2003) 263-268
19. Crilley J.G., Boehm E.A., Blair E., et al. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol 41 (2003) 1776-1782
20. Ingwall J.S., and Weiss R.G. Is the failing heart energy starved?. On using chemical energy to support cardiac function. Circ Res 95 (2004) 135-145
21. Wilding J.R., Joubert F., de Araujo C., et al. Altered energy transfer from mitochondria to sarcoplasmic reticulum after cytoarchitectural perturbations in mice hearts. J Physiol (Lond) 575 (2006) 191-200
22. Burkett E.L., and Hershberger R.E. Clinical and genetic issues in familial dilated cardiomyopathy. J Am Coll Cardiol 45 (2005) 969-981
23. Muntoni F., Cau M., Ganau A., et al. Deletion of the dystrophin muscle-promoter region associated with X-linked dilated cardiomyopathy. N Engl J Med 329 (1993) 921-925
24. Olson T.M., Michels V.V., Thibodeau S.N., Tai Y.S., and Keating M.T. Actin mutations in dilated cardiomyopathy, a heritable form of heart failure. Science 280 (1998) 750-752
25. Fatkin D., and Graham R.M. Molecular mechanisms of inherited cardiomyopathies. Physiol Rev 82 (2002) 945-980
26. Mirza M., Marston S., Willott R., et al. Dilated cardiomyopathy mutations in three thin filament regulatory proteins result in a common functional phenotype. J Biol Chem 280 (2005) 28498-28506
27. Morita H., Seidman J., and Seidman C.E. Genetic causes of human heart failure. J Clin Invest 115 (2005) 518-526
28. Sen-Chowdhry S., Syrris P., and McKenna W.J. Genetics of right ventricular cardiomyopathy. J Cardiovasc Electrophysiol 16 (2005) 927-935
29. MacRae C.A., Birchmeier W., and Thierfelder L. Arrhythmogenic right ventricular cardiomyopathy: moving toward mechanism. J Clin Invest 116 (2006) 1825-1828
30. Maron B.J. Distinguishing hypertrophic cardiomyopathy from athlete's heart: a clinical problem of increasing magnitude and significance. Heart 91 (2005) 1380-1382
31. Roberts R. Disrobing the emperor (heart) without destroying the dignity of super-normality. Circulation 105 (2002) 2934-2936
32. Morita H., Larson M.G., Barr S.C., et al. Single-gene mutations and increased left ventricular wall thickness in the community. The Framingham heart study. Circulation 113 (2006) 2697-2705
33. Priori S.G., and Napolitano C. Role of genetic analyses in cardiology: part I: mendelian diseases: cardiac channelopathies. Circulation 113 (2006) 1130-1135
34. Frenneaux M.P. Assessing the risk of sudden cardiac death in a patient with hypertrophic cardiomyopathy. Heart 90 (2004) 570-575
35. Elliott P.M., Poloniecki J., Dickie S., et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 36 (2000) 2212-2218
36. Ackerman M.J., Van Driest S.L., and Bos M. Are longitudinal natural history studies the next step in genotype-phenotype translational genomics in hypertrophic cardiomyopathy?. J Am Coll Cardiol 46 (2005) 1744-1746
37. Blair E., Redwood C., Watkins H., et al. Ascertainment strategies and genotype: phenotype correlations in hypertrophic cardiomyopathy: response. Circulation 108 (2003) 24e-25e
38. Watkins H., Rosenzweig A., Hwang D.S., et al. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med 326 (1992) 1108-1114
39. Watkins H., McKenna W.J., Thierfelder L., et al. Mutations in the genes for cardiac troponin T and (alpha)-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med 332 (1995) 1058-1065
40. Blair E., Price S.J., Baty C.J., Ostman-Smith I., and Watkins H. Mutations in cis can confound genotype-phenotype correlations in hypertrophic cardiomyopathy. J Med Genet 38 (2001) 385-388
41. Lee D.S., Pencina M.J., Benjamin E.J., et al. Association of parental heart failure with risk of heart failure in offspring. N Engl J Med 355 (2006) 138-147
42. Risch N.J. Searching for genetic determinants in the new millennium. Nature 405 (2000) 847-856
43. Herrington D. Eliminating the improbable: Sherlock Holmes and standards of evidence in the genomic age. Circulation 112 (2005) 2081-2084
44. Ortlepp J.R., Vosberg H.P., Reith S., et al. Genetic polymorphisms in the renin-angiotensin-aldosterone system associated with expression of left ventricular hypertrophy in hypertrophic cardiomyopathy: a study of five polymorphic genes in a family with a disease causing mutation in the myosin binding protein C gene. Heart 87 (2002) 270-275
45. McNamara D.M., Holubkov R., Postava L., et al. Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. J Am Coll Cardiol 44 (2004) 2019-2026
46. Loh E., Rebbeck T.R., Mahoney P.D., DeNofrio D., Swain J.L., and Holmes E.W. Common variant in AMPD1 gene predicts improved clinical outcome in patients with heart failure. Circulation 99 (1999) 1422-1425
47. Le Corvoisier P., Park H.Y., Carlson K.M., Marchuk D.A., and Rockman H.A. Multiple quantitative trait loci modify the heart failure phenotype in murine cardiomyopathy. Hum Mol Genet 12 (2003) 3097-3107
48. Brazma A., Hingamp P., Quackenbush J., et al. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet 29 (2001) 365-371
49. Rockett J.C., and Hellmann G.M. Confirming microarray data-is it really necessary?. Genomics 83 (2004) 541-549
50. Bammler T., Beyer R.P., Bhattacharya S., et al., Toxicogenomics Research Consortium. Standardizing global gene expression analysis between laboratories and across platforms. Nat Meth 2 (2005) 351-356
51. 2+ regulatory properties of reconstituted thin filaments depend on the ratio of mutant to wild-type protein. Circ Res 86 (2000) 1146-1152
52. Robinson P., Mirza M., Knott A., et al. Alterations in thin filament regulation induced by a human cardiac troponin T mutant that causes dilated cardiomyopathy are distinct from those induced by troponin T mutants that cause hypertrophic cardiomyopathy. J Biol Chem 277 (2002) 40710-40716
53. Biagini E., Coccolo F., Ferlito M., et al. Dilated-hypokinetic evolution of hypertrophic cardiomyopathy: prevalence, incidence, risk factors, and prognostic implications in pediatric and adult patients. J Am Coll Cardiol 46 (2005) 1543-1550
54. McConnell B.K., Jones K.A., Fatkin D., et al. Dilated cardiomyopathy in homozygous myosin-binding protein-C mutant mice. J Clin Invest 104 (1999) 1235-1244
55. Kang P.M., and Izumo S. Apoptosis and heart failure: a critical review of the literature. Circ Res 86 (2000) 1107-1113
56. alpha(q) transgenic mice. Circulation 108 (2003) 3036-3041
57. Foo R.S.Y., Mani K., and Kitsis R.N. Death begets failure in the heart. J Clin Invest 115 (2005) 565-571
58. Kong S.W., Bodyak N., Yue P., et al. Genetic expression profiles during physiological and pathological cardiac hypertrophy and heart failure in rats. Physiol Genomics 21 (2005) 34-42
59. Buermans H.P.J., Redout E.M., Schiel A.E., et al. Microarray analysis reveals pivotal divergent mRNA expression profiles early in the development of either compensated ventricular hypertrophy or heart failure. Physiol Genomics 21 (2005) 314-323
60. Sanoudou D., Vafiadaki E., Arvanitis D.A., Kranias E., and Kontrogianni-Konstantopoulos A. Array lessons from the heart: focus on the genome and transcriptome of cardiomyopathies. Physiol Genomics 21 (2005) 131-143
61. Lowes B.D., Zolty R., Minobe W.A., et al. Serial gene expression profiling in the intact human heart. J Heart Lung Transplant 25 (2006) 579-588
62. Beisvag V., Lehre P.K., Midelfart H., et al. Aetiology-specific patterns in end-stage heart failure patients identified by functional annotation and classification of microarray data. Eur J Heart Failure 8 (2006) 381-389
63. Terracciano C.M.N., Hardy J., Birks E.J., Khaghani A., Banner N.R., and Yacoub M.H. Clinical recovery from end-stage heart failure using left-ventricular assist device and pharmacological therapy correlates with increased sarcoplasmic reticulum calcium content but not with regression of cellular hypertrophy. Circulation 109 (2004) 2263-2265
64. Margulies K.B., Matiwala S., Cornejo C., Olsen H., Craven W.A., and Bednarik D. Mixed messages: transcription patterns in failing and recovering human myocardium. Circ Res 96 (2005) 592-599
65. Hwang J.J., Allen P.D., Tseng G.C., et al. Microarray gene expression profiles in dilated and hypertrophic cardiomyopathic end-stage heart failure. Physiol Genomics 10 (2002) 31-44
66. Steenbergen C., Afshari C.A., Petranka J.G., et al. Alterations in apoptotic signaling in human idiopathic cardiomyopathic hearts in failure. Am J Physiol Heart Circ Physiol 284 (2003) H268-H276
67. Liew C.C., and Dzau V.J. Molecular genetics and genomics of heart failure. Nat Rev Genet 5 (2004) 811-825
68. Kittleson M.M., Ye S.Q., Irizarry R.A., et al. Identification of a gene expression profile that differentiates between ischemic and nonischemic cardiomyopathy. Circulation 110 (2004) 3444-3451
69. Tan F.L., Moravec C.S., Li J., et al. The gene expression fingerprint of human heart failure. Proc Natl Acad Sci U S A 99 (2002) 11387-11392
70. Cunha-Neto E., Dzau V.J., Allen P.D., et al. Cardiac gene expression profiling provides evidence for cytokinopathy as a molecular mechanism in Chagas' disease cardiomyopathy. Am J Pathol 167 (2005) 305-313
71. Rajan S., Williams S.S., Jagatheesan G., et al. Microarray analysis of gene expression during early stages of mild and severe cardiac hypertrophy. Physiol Genomics 27 (2006) 309-317
72. Frey N., Brixius K., Schwinger R.H.G., et al. Alterations of tension-dependent ATP-utilization in a transgenic rat model of hypertrophic cardiomyopathy. J Biol Chem 281 (2006) 29575-29582
73. Morgun A., Shulzhenko N., Perez-Diez A., et al. Molecular profiling improves diagnoses of rejection and infection in transplanted organs. Circ Res 98 (2006) e74-e83
74. Mann D.L., and Bristow M.R. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 111 (2005) 2837-2849
75. Stanley W.C., Recchia F.A., and Lopaschuk G.D. Myocardial Substrate Metabolism in the Normal and Failing Heart. Physiol Rev 85 (2005) 1093-1129
76. Kittleson M.M., and Hare J.M. Molecular signature analysis: using the myocardial transcriptome as a biomarker in cardiovascular disease. Trends Cardiovasc Med 15 (2005) 130-138
77. Lee L., Campbell R., Scheuermann-Freestone M., et al. Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation 112 (2005) 3280-3288
78. Roberts R., and Sigwart U. Current concepts of the pathogenesis and treatment of hypertrophic cardiomyopathy. Circulation 112 (2005) 293-296
79. Megevand A., Ingles J., Richmond D.R., and Semsarian C. Long-term follow-up of patients with obstructive hypertrophic cardiomyopathy treated with dual-chamber pacing. Am J Cardiol 95 (2005) 991-993
80. Maron B.J., Nishimura R.A., McKenna W.J., Rakowski H., Josephson M.E., and Kieval R.S. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation 99 (1999) 2927-2933
81. Strom C.C., Aplin M., Ploug T., et al. Expression profiling reveals differences in metabolic gene expression between exercise-induced cardiac effects and maladaptive cardiac hypertrophy. FEBS J 272 (2005) 2684-2695
82. Li J., and Burmeister M. Genetical genomics: combining genetics with gene expression analysis. Hum Mol Genet 14 Spec No 2 (2005) R163-R169
83. Whitney A.R., Diehn M., Popper S.J., et al. Individuality and variation in gene expression patterns in human blood. Proc Natl Acad Sci U S A 100 (2003) 1896-1901